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Objectives: Hypopharyngeal squamous cell carcinoma (SCC) is a rare but aggressive 
malignancy, with low survival rates and high incidence of tumor and treatment-related 
morbidity. This study aims to analyze the long-term oncologic and functional outcomes 
of a large cohort of patients and to determine prognostic factors. 
Methods: The records of all patients diagnosed with hypopharyngeal SCC and treated 
with curative intent at our tertiary referral center were reviewed. Patient and initial 
disease characteristics, features and complications of primary treatment, recurrence 
patterns and corresponding treatments and the oncologic and functional long-term 
outcome were determined. 
Results: For a total of 179 patients primary radiotherapy (RT) was the predominant 
treatment modality (78%), whereas 22% underwent primary surgery. The median, 2-
year and 5-year overall survival (OS) for the study cohort was 47 months, 64% and 
43%. The median survival after first and second relapse was seven and six months, 
respectively. The 2 and 5-year relapse-free survival (RFS) was 52% and 36%. The 
median RFS after first relapse and salvage treatment was nine months. A nodal status 
of ≥cN2 (HR=1.89, CI:1.21-3.05, p<0.005) and any other primary tumor localization 
than pyriform sinus (HR=1.60, CI: 1.04-2.42, p<0.05) were identified as independent 
risk factors for shorter OS and RFS. Regarding functional outcome, the 2- and 5-year 
laryngectomy-free-survival was 55% and 37%, respectively. 
Conclusion: In this large cohort with long-term follow-up any other primary tumor 
localization than pyriform sinus and a nodal status of ≥cN2 were identified as risk 
factors for reduced OS and RFS. 
 
Key words: hypopharyngeal cancer, oncologic outcome, functional outcome, relapse, 
quality of life, tracheostomy, feeding tube 
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Level of evidence: 4 
Introduction 
Hypopharyngeal squamous cell carcinoma (SCC) is a rare malignancy accounting for 
approximately 3% to 5% of all head and neck cancers, with poor survival rates.1 This 
may be explained by late appearance of symptoms, aggressive local growth, extensive 
submucosal spread, anatomical proximity to the larynx, high rates of lymph node 
involvement and a high incidence of distant metastasis (up to 60%) at initial 
presentation or during follow-up.2-4 Moreover, almost 50% of the patients are affected 
by recurrences, mostly occurring within 12 months after completion of treatment.5 
Predisposition to develop secondary malignancies due to smoking, associated 
significant comorbid illnesses, common association with major alcohol abuse and 
frequent nutritional depletion are known factors worsening the prognosis of 
hypopharyngeal SCC.1 
Treatment strategies have changed significantly over the past few decades. The 
traditional treatment approach for locally advanced hypopharyngeal SCC has been 
pharyngo-laryngectomy (PL), with or without adjuvant radiotherapy +/- chemotherapy.1 
However, radical surgery and subsequent reconstructive procedures may result in 
deterioration or loss of speech and swallowing functions, and accordingly in poor 
quality of life.2 The necessity for improving survival along with functional improvements 
with larynx preservation to maintain the functions of speech and respiration, led to 
organ preservation approaches such as induction chemotherapy followed by 
radiotherapy in good responders or definitive concurrent chemoradiotherapy.6,7 These 
strategies have become common with comparable outcomes (equivalent survival rates 
and locoregional control (LRC)) to surgical approaches.8 However, toxicity is high after 
chemoradiotherapy and is associated with considerable side effects such as 
xerostomia, mucositis and later fibrosis contributing to decreased oral intake.2 
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Dysphagia can ultimately lead to malnutrition, severe weight loss, permanent 
tracheostomy, gastrostomy tube dependence, pharyngo-esophageal stenosis 
requiring dilatation and aspiration pneumonia which may lead to death.9,10 
Until today, the ideal treatment strategy for advanced hypopharyngeal SCC is a matter 
of discussion.1,11 There is also a lack of understanding of the course of disease of this 
tumor due to the low incidence, the poor prognosis and the outcomes biased by the 
patient treatment selection of case series and observational studies.11 This single-
institution retrospective study of an academic tertiary referral center aims to analyze 
the prognostic factors and report on survival, relapse patterns and long-term functional 
outcome of patients diagnosed with and curatively treated for hypopharyngeal SCC.  
 
Material and Methods 
Our institutional and regional review board (Inselspital, Bern University Hospital, Bern, 
Switzerland, KEK Nr. 117/14) granted approval to perform the present study.  
The paper and electronic records of all patients diagnosed with hypopharyngeal SCC 
between 2003 and 2015 at our tertiary referral center were reviewed (n=270). A total 
of 91 patients were excluded due to: a) non-curatively intended treatment (palliative 
situations) (n=39), b) presence of any synchronous (n=26) or c) previously diagnosed 
(n=26) malignant tumor. Finally, 179 patients with accomplished curatively intended 
treatment were enrolled in the present study.  
Patient’s and initial disease characteristics were assessed and staged with the Union 
for International Cancer Control (UICC) 7th edition. Features and complications of 
primary treatment, recurrence patterns and corresponding treatments and the 
oncologic and functional long-term outcome at last follow-up were documented. 
The time-to-event outcomes were calculated based on the date of diagnosis, and 
evaluated by Kaplan-Meier curves and log-rank test. In order to isolate the adverse 
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factors influencing the outcome parameters, multivariate Cox proportional hazard and 
nominal logistic models with variables yielding p values <0.1 via univariate analyses 
were built, and backwards elimination was performed. Statistical analysis was done 
with JMP software (version 14.0 SAS Institute, Cary, NC, USA). Statistical significance 
was set to a two-tailed alpha of <0.05. The actuarial rates and risk estimations were 
calculated with 95% confidence intervals (CI). 
 
Results 
Initial patient’s and disease characteristics (n=179) are summarized in Table 1. Median 
follow-up of surviving patients was 51.5 months. Primary radiotherapy was the 
predominant treatment modality (78%), whereas 22% underwent primary surgery. 
Induction chemotherapy with was given to 19 patients (10.6%) followed by primary 
radiotherapy (n=18) or surgery (n=1). Forty-six patients underwent up-front neck 
dissection (ND) prior to primary radiotherapy and 122 patients received primary 
radiotherapy with concomitant chemotherapy (three-weekly cisplatin n=75, carboplatin 
and 5-fluoruracil n=11, weekly cetuximab n=29, missing information n=7).  
For 100 patients, primary radiotherapy was delivered by intensity modulated 
techniques (static field n=46 and volumetric modulated arc n=54 with sequential boost 
technique: 54/72 Gy), The remaining 39 received the primary radiotherapy with 3-
dimensional conformal technique. The standard total dose was 72 Gy in 2 Gy daily 
fractions (prescribed at median, D95% of PTV ≥ 95%). However, the treatment was 
interrupted between 66 and 70 Gy in 13 patients due to toxicity or patients’ decision, 
and boosted up to 78 Gy in 3 patients in order to compensate for treatment breaks. 
The 40 primary surgically treated patients underwent either transoral resection (23 
patients), partial open laryngectomy (3 patients) or PL (14 patients). The surgical defect 
was reconstructed by pectoralis major myocutaneous flap in 4 patients, by radialis free 
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flap in one patient and by gastric pull-up in one patient, whereas primary closure of the 
defect was possible in the remaining patients. Twenty-nine patients underwent ND with 
primary tumor surgery. Thirty-two of the 40 surgically treated patients (80%) received 
adjuvant radiotherapy (intensity modulated n=18) with the standard prescribed dose of 
66 Gy in 2 Gy daily fractions. However, one patient received 64 Gy, and ten patients 
received higher doses between 68 and 72 Gy due to various reasons (e.g. 
compensation for treatment breaks, R2 resection, suspicious post-operative lymph 
nodes).  and 18 of them Eighteen patients received concomitant chemotherapy (three-
weekly cisplatin n=14, carboplatin and 5-fluoruracil n=4).  
 
Oncologic Outcomes 
Figure 1 illustrates overall and relapse-free survival (RFS) curves. The median, 2- and 
5-year overall survival (OS) for the study cohort was 47 months, 64% and 43%, 
respectively. The median, 2- and 5-year RFS for the study cohort was 25 months, 52% 
and 36%, respectively. The 2- and 5-year LRC was 65% and 58%, respectively. The 
median survival after first relapse was 7 months (21 months with and 6 months without 
salvage therapy) and the median survival after second relapse was 6 months. The 
median RFS after first relapse and salvage treatment was 9 months. 
Tumor recurrence was observed in 88 patients (49%), a second relapse in 16 patients 
(9%). Fifty-five patients (30.7%) were alive and without evidence of disease at last 
follow-up, whilst 17 patients (9.5%) were alive with persistent or recurrent disease. 
Thirty-seven patients (20.7%) died free of disease, whilst 70 patients (39.1%) died with 
disease.  
The multivariate analysis revealed as independent risk factors for shorter OS and RFS 
any primary tumor localization other than pyriform sinus and the presence of a nodal 
status of cN2 and higher. In contrast, other factors assessed in the multivariate analysis 
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as gender, age and tumor (T-stage) were not significantly associated with a shorter 
OS and RFS. The results of the multivariate analysis are summarized in Table 2a. 
 
Risk of Tracheotomy/Pharyngo-laryngectomy and Feeding Tube 
The incidence of undergoing a PL and/or tracheotomy at any time point was 47%, (PL: 
13%, n=24). The risk of requiring a feeding tube (FT) at any time point was 71.5%. 
Similarly, 73 patients (41%) had a tracheotomy and/or PL at last follow-up, and 78 
patients (43.6%) had a FT at last follow-up. Advanced tumor size (cT≥3), higher nodal 
status (cN≥2) and any primary tumor localization other than pyriform sinus remained 
as adverse factors for LFS after backwards elimination. The results of the multivariate 
analysis are summarized in Table 2b. Further information on tracheostomy and 
feeding tube categorized by primary therapy are summarized in Table 3. 
The 2- and 5-year laryngectomy-free-survival (LFS) for the study cohort was 55% and 
37%, respectively (Figure 2A). Figure 2B depicts the LFS distributed for initial tumor 
size and extent, grouped as early (T1-T2) and locally-advanced (T3-T4).  
 
Early and Late Complications 
Four patients (2.9%) died within 30 days after primary radiotherapy. Three of them died 
from tumor hemorrhage and one from multiorgan dysfunction. Furthermore, the 
following complications were clinically observed: hypopharyngeal stenosis (66%), 
laryngeal stenosis (35%), soft tissue necrosis/flap failure/fistula (8%) and 
chondroradionecrosis (4%). Further information on complications categorized by 






Outcome after Salvage Treatment  
Tumor recurrence was observed in 88 patients (49%); of those 16 (18%) were treated 
with surgical salvage, 3 (3.5%) with salvage radiotherapy, and 9 (10%) with both 
combined. Sixty patients (68.5%) required or requested palliative treatment or best 
supportive care. Table 4 provides additional information on the patterns and treatment 
of first relapse.  
Four patients died during or within 30 days after the salvage treatment (tumor 
hemorrhage: 1 patient, pulmonary embolism: 1 patient, multiorgan dysfunction: 1 
patient, postoperative cardiac arrhythmia: 1 patient). Following additional rates of 
complications were observed: FT requirement/hypopharyngeal stenosis (63.6%), 
laryngeal stenosis (30.7%), soft tissue necrosis/flap failure/fistula (12.5%), aspiration 
pneumonia (4.5%) and chondroradionecrosis (1%). 
A second relapse occurred in 16 patients (9%). The mean time interval between first 
and second recurrence was 10.6 months (range: 0-127). Eleven patients required or 
requested palliative treatment, 6 of them received chemotherapy, 3 received 
radiotherapy. Only five patients were treated with curative intent by salvage surgery 
(n=3) or salvage radiotherapy (n=2).  
 
Discussion 
In this study, we report long-term oncologic and functional outcome after curatively 
intended hypopharyngeal SCC treatment of all non-distant metastatic tumor stages. 
The 5-year OS and RFS was 43% vs. 36%, respectively. Fifty-five (30.7%) out of 179 
patients were alive and without evidence of disease at last follow-up. The multivariate 
model identified any primary tumor localization other than pyriform sinus and a nodal 
status of cN≥2 as risk factors for reduced OS and RFS. The 5-year LFS was 37%. 
Overall, any tracheostomy and/or PL and FT were observed in 46.9% and 71.5% of 
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the whole cohort within all stages, respectively. Of those, 40.8% had a tracheostomy 
and/or PL at last follow-up and 43.6% remained dependent on FT.  
Hypopharyngeal SCC is a rare but aggressive malignancy with low survival rates 
confirmed by our results.  Similarly, a study by Joo et al. (2011) identified advanced 
stage neck disease (pN≥2) and posterior pharyngeal wall subsite as risk factors for 
disease-specific survival (DSS) in hypopharyngeal SCC patients with larynx-
preserving partial hypopharyngectomy with or without postoperative radiotherapy.8 
Taguchi et al. (2013) also showed that N stage (cN≥2c) is a significant prognostic factor 
of DSS for patients with advanced SCC of the hypopharynx undergoing 
chemoradiotherapy. Even with the high-dose regimen, patients with advanced nodal 
disease, especially cN≥2c, had low DSS rates.12  
Since the negative influence of a higher nodal burden has been emphasized several 
times, it can be assumed that such patients would probably benefit from a planned ND. 
Thariat et al. (2010) investigated the need for planned ND after (chemo)radiotherapy 
for node positive patients with carcinomas of the pharynx and larynx. They found little 
justification for systematic ND after (chemo)radiotherapy. The majority of patients with 
complete response to (chemo)radiotherapy did not undergo ND and had a 5-year neck 
control rate of 92%. After partial response, the addition of a ND resulted in higher neck 
control. In conclusion, patients with complete response could be observed, patients 
with partial response benefit from a ND to prevent regional relapse according to this 
study.13 
Our study suggests not only a high nodal status (cN≥2), but also any primary subsite 
other than pyriform sinus as independent risk factor for OS and RFS in hypopharyngeal 
SCC patients. However, we have to consider whether tumors of the pyriform sinus can 
be detected and treated earlier and easier, for example by endoscopy. Furthermore, 
larger tumors in our study were categorized as "multiple localizations". This rather 
 
 10 
imprecise term certainly includes some locally advanced tumors including the pyriform 
sinus, where the primary site was indeterminable. 
In this investigation, tumor recurrence was observed in 88 patients (49%) after primary 
treatment, of those 57.5% and 46.8% in the primary surgery and primary radiotherapy 
subgroups, respectively. Since salvage therapy involves a high morbidity rate in a 
patient collective with poor life expectancy, we have to raise the question whether the 
resulting benefit for the patient justifies the effort and the associated morbidity. In our 
cohort, 16 patients (57% of the 28 patients with curatively intended treatment for first 
relapse) ended up with a second relapse. Only five of them could be treated with 
curative intent. The median survival after first relapse was 7 months (21 with salvage 
therapy, 6 without) and the median survival after second relapse was 6 months. The 
median RFS after first relapse and salvage treatment was 9 months. It is the duty of 
the treating multidisciplinary team to evaluate survival and functional results and their 
impact on patient’s quality of life to adequately counsel the patients. Finally, the patient 
should be able to make an informed decision and have the possibility to trade off 
chance of survival against treatment related morbidity.14,15 
Due to the relative lack of symptoms for early-stage of disease, the majority of patients 
with hypopharyngeal SCC present with locoregionally advanced disease at the time of 
their diagnosis with a substantial risk of subclinically present distant metastatic 
spread.16 Approximately 60-80% of the patients with newly diagnosed hypopharyngeal 
SCC already have clinically apparent ipsilateral and up to 40% have contralateral neck 
lymph node involvement. Hypopharyngeal tumors generally affect the lymph nodes 
more often than laryngeal tumors and if they are involved, this is more likely to lead to 
death than laryngeal tumors with affected lymph nodes.5  
Furthermore, patients with hypopharyngeal SCC generally have a poor functional 
outcome. In our cohort any kind of tracheostomy (including PL) was observed in 46.9% 
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of patients, of which 40.8% were permanent tracheostomies (50% surgical and 38.1% 
RT group). Regarding permanent FT dependency similar numbers were observed with 
43.6% permanent FT placement (32.5% surgical and 46.8% RT group). These 
numbers indicate a high morbidity of hypopharyngeal SCC treatment. Petersen et al. 
(2019) assessed in a recent study the functional outcomes of hypopharyngeal SCC 
patients treated with radiotherapy or chemoradiotherapy. Functional outcome was 
measured using laryngo-oesophageal dysfunction-free survival rate (LDFS). The 2-
year and 5-year LDFS following chemoradiotherapy was higher than the corresponding 
rate following radiotherapy. In summary, functional outcomes following 
chemoradiotherapy or radiotherapy appear to be disappointing and demand improved 
treatment strategies.17 
New therapeutic approaches are constantly being developed and investigated in order 
to improve the functional outcome of these patients with the aim of achieving similar 
survival rates. A positive influence of induction chemotherapy on the long-term 
functional outcome of hypopharyngeal SCC patients subsequently treated with 
(chemo)radiotherapy could be shown. Vourexakis et al. (2014) evaluated the following 
functions: oral communication, airway patency and oral feeding. The subjects were 
good responders to induction chemotherapy for pyriform sinus SCC (n=28), 
subsequently treated with adjuvant radiotherapy, with (n=13) or without (n=15) 
concomitant chemotherapy. Only 7% of patients in their study needed a tracheostomy 
during or after treatment and only 7% had PL for a late local relapse. At least 3 years 
after the end of therapy, all patients were exclusively fed by mouth and the majority of 
them didn’t need to modify their eating habits. All patients judged their voice 
performance as adequate for everyday oral communication. Therefore, patients with 
hypopharyngeal SCC who respond favorably to induction chemotherapy present a 
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good functional outcome when treated with (chemo)radiotherapy. Nevertheless, it is 
important to note that these data do not provide a high level of evidence.18 
Chen et al. (2017) studied the effect of daily fraction size on laryngoesophageal 
dysfunction among patients treated by chemoradiotherapy for locally advanced SCC 
of the larynx and hypopharynx. When comparing 2 versus > 2 Gy daily fractionation, 
there was no difference in 2-year OS, LFS and LRC. But they were able to show a 
difference in LDFS. Use of 2 Gy versus > 2 Gy fractionation improved LDFS (2-year 
LDFS 49% vs. 27%, respectively), as well as patient-reported swallowing function and 
voice.10 
In the last few years, the quest for surgical treatment options offering conserved 
laryngeal function led to the development and validation of partial transoral and open 
surgeries. Hung et al. (2017) demonstrated transoral laser microsurgery (TLM) 
achieving good oncologic results and satisfactory speech and swallowing function, in 
patients with early and selective moderately advanced hypopharyngeal SCC. The 5-
year OS and DSS rates were 59% and 77%, respectively. The 5-year laryngeal-
preservation rate was 89%. They explained their results by the reduced need for 
radiotherapy in primary surgical treatment and by reduced radiotherapy dose in 
postoperative radiotherapy compared to primary radiotherapy.2 
We acknowledge the limitations of the present study mainly due to its retrospective 
nature and its inherent challenges, for example, the possible presence of confounding 
variables, the vulnerability to the development of a selection bias and the fact that we 
cannot determine causation, only association. Besides, our study has an asymmetry 







In this study, we report long-term oncologic and functional outcome after curatively 
intended hypopharyngeal SCC treatment of all loco-regionally confined tumor stages. 
Any primary tumor localization other than pyriform sinus and nodal status cN≥2 are 
related to a poorer OS and RFS. Advanced tumor size (cT≥3), any primary tumor 
localization other than pyriform sinus and nodal status cN≥2 seem to be adverse 
factors impairing LFS. In this cohort permanent tracheostomy placement was observed 
in 40.8% and permanent FT dependency in 43.6% of patients. Appropriate patient 
selection may be the key to improve oncologic and functional outcomes and should be 
discussed by multidisciplinary teams. 
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Table I: Patient’s and initial disease characteristics 
 Whole Cohort 
Primary Surgery 




or without systemic 
treatment 
Parameter n n n 
Total  179 40 139 
Male sex 155 (87%) 35 (87.5%) 120 (86.3%) 
Median age, years (range) 59 (35-87) 57.5 (44-81) 59 (35-87) 
Tumor subsite    
Sinus pyriformis 134 (75%) 29 (72.5%) 105 (75.5%) 
Posterior pharyngeal wall 17 (9%) 2 (5%) 15 (10.8%) 
Post-cricoid region 2 (1%) 1 (2.5%) 1 (0.7%) 
Multiple subsites involved 26 (15%) 8 (20%) 18 (13%) 
cT stage    
1 17 (9%) 9 (22.5%) 8 (5.8%) 
2 50 (28%) 7 (17.5%) 43 (30.9%) 
3 48 (27%) 7 (17.5%) 41 (29.5%) 
4a 59 (33%) 17 (42.5%) 42 (30.2%) 
4b 5 (3%) 0 (0%) 5 (3.6%) 
cN stage    
0 45 (25%) 15 (37.5%) 30 (21.6%) 
1 17 (10%) 3 (7.5%) 14 (10%) 
2 113 (63%) 21 (52.5%) 92 (66.2%) 
3 4 (2%) 1 (2.5%) 3 (2.2%) 
Clinical UICC7th ed. Stage    
I 9 (5%) 7 (17.5%) 2 (1.4%) 
II 17 (9.5%) 2 (5%) 15 (10.8%) 
III 22 (12.3%) 4 (10%) 18 (13%) 
IVA 124 (69.3%) 26 (65%) 98 (70.5%) 





Table II: Multivariate model after backwards elimination for overall survival, relapse-
free survival and locoregional relapse 
 
Variable HR for overall 
survival  
(95% CI) 
p value HR for relapse-
free survival 
(95% CI) 




cN≥2 1.89 (1.21-3.05) <0.005 1.56 (1.05-2.36) <0.05 1.44 (0.87-2.47) 0.161 
Subsite other than 
pyriform sinus 
1.60 (1.04-2.42) <0.05 1.74 (1.16-2.55) <0.05 1.50 (0.40-1.16) 0.149 
Age>59 1.35 (0.92-1.98) 0.126 1.23 (0.87-1.75) 0.2456 1.03 (0.65-1.65) 0.881 
Male sex 1.47 (0.81-2.95) 0.217 1.47 (0.37-1.17) 0.169 1.49 (0.29-1.35) 0.278 
cT≥3 1.18 (0.76-1.86) 0.464 0.90 (0.61-1.34) 0.5976 0.82 (0.50-1.38) 0.447 
HR: hazard ratio; CI: confidence interval 
 
Table III: Multivariate Cox proportional hazards model for laryngectomy-free survival  
 
Variable Multivariate model 
HR (95% CI) 
 
p value 
After backwards elimination 
HR (95% CI) 
 
p value 
cN≥2 1.65 (1.07-2.61) <0.05 1.66 (1.08-2.63) <0.05 
Subsite other than 
pyriform sinus 
1.83 (1.21-2.71) <0.005 1.80 (1.19-2.66) <0.05 
cT≥3 1.49 (0.98-2.33) 0.0621 1.54 (1.01-2.39) <0.05 
Age>59 0.94 (0.65-1.36) 0.7512   
Male sex 1.35 (0.76-2.60) 0.318   





Table IV: Complications and functional outcome after first treatment 
 
 Whole Cohort 
Primary Surgery 





with or without 
systemic 
treatment 
Parameter n n n 
Total  179 40 139 
Hypopharyngeal stenosis 118 (66%) 18 (45%) 100 (72%) 
Operative dilatation  11 (6%) 2 (5%) 9 (6.5%) 
Laryngeal stenosis 63 (35%) 21 (52.5%) 56 (40.3%) 
Asymptomatic (observation) 1 (0.5%) 0 (0%) 1 (0.7%) 
Symptomatic without    





Limiting self-care 1 (0.5%) 1 (2.5%) 3 (2.2%) 
Life-threatening 57 (32%) 5 (12.5%) 52 (37.4%) 
Chondroradionecrosis 7 (4%) 2 (5%) 5 (3.6%) 
Soft tissue necrosis, flap failure, 





Any tracheostomy* 84 (46.9%) 21 (52.5%) 63 (45.3%) 
Permanent tracheostomy* 73 (40.8%) 20 (50%) 53 (38.1%) 
Any feeding tube 128 (71.5%) 22 (55%) 106 (76.3%) 
Permanent feeding tube 78 (43.6%) 13 (32.5%) 65 (46.8%) 
Death due to treatment 









Table V: First relapse and its treatment 
 Whole Cohort 
Primary Surgery 




or without systemic 
treatment 
Parameter n n n 
Total  88 (49% of 179) 23 (57.5% of 40) 65 (46.8% of 139) 
Localization of first relapse    
Local 32 (36%) 8 (34.8%) 24 (36.9%) 
Isolated regional 12 (14%) 7 (30.4%) 5 (7.7%) 
Locoregional 9 (10%) 3 (13%) 6 (9.2%) 
Locoregional and distant 21 (24%) 2 (8.7%) 19 (29.2%) 
Distant only 14 (16%) 3 (13%) 11 (16.9%) 
Localization of distant 
metastases 35 (40% of 88) 
  
Pulmonary 14 (40%) 2 (40%) 12 (40%) 
Bone 5 (14.3%) 2 (40%) 3 (10%) 
Liver 1 (2.9%) 0 (0%) 1 (3.3%) 
Other 4 (11.4%) 0 (0%) 4 (13.3%) 
Multiple sites 11 (31.4%) 1 (20%) 10 (33.3%) 
Treatment    
Salvage surgery  16 (18%) 6 (26.1%) 10 (15.2%) 
Salvage RT 3 (3.4%) 2 (8.7%) 1 (1.5%) 
Salvage surgery + RT  9 (10.1%) 4 (17.4%) 5 (7.6%) 
Palliative chemotherapy 30 (33.7%) 4 (17.4%) 26 (39.4%) 
Palliative RT 6 (6.7%) 1 (4.3%) 5 (7.6%) 
Palliative RT + chemotherapy 1 (1.1%) 0 (0%) 1 (1.5%) 
Best supportive care 24 (27%) 6 (26.1%) 18 (27.3%) 
Type of salvage surgery 25 (28.4% of 88) 10 15 
ND only  9 (36%) 6 (60%) 3 (20%) 
Open partial  





Open total  





Transoral partial  





Lung wedge resection 1 (4%) 0 (0%) 1 (6.7%) 
Flap for salvage  9 (36%) 2 (20%) 7 (50%) 











Figure 1: Overall and relapse free survival for the whole cohort  
 
Figure 2: Panel A: Laryngectomy-free survival for the whole cohort and B: by cT 
stage  
